{
    "title": "108_s2053",
    "content": "The Act titled \"Medicare Enhancements for Needed Drugs Act of 2004\" requires GAO studies and reports on prescription drug prices. The \"Medicare Enhancements for Needed Drugs Act of 2004\" mandates GAO reviews and reports on retail prices of prescription drugs, focusing on drugs used by individuals aged 65 or older from 2000 to 2003. The Comptroller General will conduct an initial review and subsequent reviews until April 1, 2006, to track cost changes, with reports due to Congress by specified dates. The Comptroller General will conduct ongoing reviews comparing retail and acquisition prices of the top 20 prescription drugs for individuals aged 65 or older in the US. Reports will be submitted to Congress by specific dates. The Comptroller General will compare drug acquisition prices under different programs and report findings to Congress annually. The Comptroller General will submit an annual report to Congress on the study conducted on drug acquisition prices, along with recommendations. SEC. 3. INCLUSION OF AVERAGE AGGREGATE BENEFICIARY COSTS AND SAVINGS IN COMPARATIVE INFORMATION FOR BASIC MEDICARE PRESCRIPTION DRUG PLANS. Section 1860D-1(c)(3) of the Social Security Act is amended to include average aggregate beneficiary costs and savings for covered part D drugs in Medicare Prescription Drug plans starting from January 1, 2007. The Social Security Act is amended to include average aggregate beneficiary costs and savings information for Medicare Prescription Drug plans, excluding certain plans like those providing supplemental coverage or Medicare Advantage plans. SEC. 4. NEGOTIATING FAIR PRICES FOR MEDICARE PRESCRIPTION DRUGS. The amendment to the Social Security Act allows the Secretary to negotiate prices with manufacturers of covered part D drugs to ensure beneficiaries pay the lowest possible price. This amendment aims to provide quality care and contain costs under Medicare. The amendment allows the Secretary to negotiate prices with manufacturers of covered part D drugs to ensure beneficiaries pay the lowest possible price, with the same effect as if included in the enactment of section 101 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. SEC. 5. DISALLOWANCE OF DEDUCTION FOR ADVERTISING EXPENDITURES OF TAXPAYERS WHO DISCRIMINATE AGAINST FOREIGN SELLERS OF PRESCRIPTION DRUGS TO DOMESTIC CONSUMERS. This section amends the Internal Revenue Code to disallow deductions for advertising expenses of taxpayers who discriminate against foreign sellers of prescription drugs to domestic consumers. No deduction allowed for advertising expenses if taxpayer discriminates against qualified pharmacy or wholesaler in selling prescription drugs. Advertising includes direct to consumer promotions and activities to promote prescription drug use. Qualified pharmacy defined as foreign pharmacy selling drugs to US consumers. The text discusses the definition of a qualified wholesaler as a wholesaler located outside the United States selling prescription drugs to entities in the US. It also mentions that taxpayers cannot discriminate against qualified pharmacies or wholesalers in selling prescription drugs. Section 280I prohibits taxpayers from discriminating against foreign sellers of prescription drugs to domestic consumers. The amendments apply to taxable years after the enactment of the Act. The Social Security Act is amended to provide incentive payments to PDP sponsors for offering prescription drug plans with negotiated prices not exceeding 10 percent above certain benchmarks. The Social Security Act is amended to provide incentive payments to PDP sponsors for offering prescription drug plans with negotiated prices not exceeding 10 percent above certain benchmarks. The Secretary of Health and Human Services can request information from the Department of Defense and the Department of Veterans Affairs regarding acquisition prices of prescription drugs for the incentive payment program. Incentive payments can only be made under this subsection with an approved application submitted in the specified manner. The Secretary can request information from the Department of Defense and the Department of Veterans Affairs for incentive payments. $500,000,000 is available for incentive payments from the MA Regional Plan Stabilization Fund. Annual reports must be submitted to Congress for each incentive payment awarded. The amendment increases the number of incentive payments to PDP sponsors and specifies the effective date as the enactment of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. The Secretary will request the NAIC to review changes in Medigap policies providing prescription drug coverage under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. The focus of the review should be on the impact on Medicare beneficiaries."
}